Therapies currently in Phase II trials for malignant pleural mesothelioma

Expert Opinion on Investigational Drugs

Volumn 22, Issue 10, 2013, Pages 1255-1263

  Pinton, Giulia ^a   Manente, Arcangela Gabriella ^a   Tavian, Daniela ^b   Moro, Laura ^a   Mutti, Luciano ^c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c Vercelli Hospital   (Italy)

Author keywords

Clinical trial; Mesothelioma; Phase II; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ASBESTOS; CEDIRANIB; CISPLATIN; CIXUTUMUMAB; DOVITINIB; HSV 1716; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PEMETREXED; PF 03446962; TICILIMUMAB; UNCLASSIFIED DRUG; WT 1; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTIGEN SPECIFICITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; EXPOSURE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84884228160     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.816281     Document Type: Review

References (58)

1. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103(38):14128-33
2. Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 2010;107:12611-16
3. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65(12):5256-62
4. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43(10):1022-5
5. Ugolini D, Neri M, Ceppi M, et al. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. Mutat Res 2008;658(3):162-71.Review
6. Landi S, Gemignani F, Neri M, et al. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. Int J Cancer 2007;120(12):2739-43
7. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009;136:888-96. Review
8. Blayney JK, Ceresoli GL, Castagneto B, et al. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 2012;48:2983-92
9. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Society/European Society of Thoracic Surgeons Task Force. Eur Respir J 2010;35:479-95
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193(4):468-75
11. Kawaguchi K, Murakami H, Taniguchi T, et al.combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009;30(7):1097-105
12. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006;51(2):207-15
13. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13(7):e301-10.Review
14. Krug LM, Dao T, Brown AB, et al. Scheinberg WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1467-79
15. Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005;19:1318-23
16. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010;181:1383-90
17. Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. Natl Compr Canc Netw 2012;10(1):42-7
18. Garland LL, Rankin C, Gandara DR, et al Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-13
19. Govindan R, Kratzke RA, Herndon JE II, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300-4
20. Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6
21. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-50
22. Pinton G, Manente AG, Angeli G, et al. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE 2012;7(5):e36856
23. Pinton G, Thomas W, Bellini P, et al. Estrogen receptor b exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 2010;5(11):e14110
24. Gregorc V, Zucali PA, Santoro A. Phase II study of asparagine- glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010;28(15):2604-11
25. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85(6):863-8
26. Ceresoli GL, Zucali PA. Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin Investig Drugs 2012;21(6):833-44
27. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509-15
28. McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs 2009;18(7):1025-33
29. Kai K, D'Costa S, Sills RC, Kim Y. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009;278(1):49-55
30. Kalra N, Zhang J, Yu Y, et al. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. Int J Cancer 2012;131(9):2143-52
31. Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17(23):7451-61
32. Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 2013;12(5):632-42
33. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011;6(11):1938-45
34. Hofmann M, McCormack E, Mujic M, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia 2009;11:812-22
35. Hinck AP. Structural studies of the TGF-bs and their receptors -insights into evolution of the TGF-b superfamily. FEBS Lett 2012;586(14):1860-70.Review
36. Massagué J. TGFbeta in cancer. Cell 2008;134:215-30
37. Goumans MJ, Liu Z, ten-Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-27
38. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117(26):6999-7006
39. Hu-Lowe DD, Chen E, Zhang L, et al. Targeting activin receptor-like kinase 1 (alk1) inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-vegf therapies. Cancer Res 2011;71(4):1362-73
40. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18(11):1185-90
41. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 2004;1028:104-12
42. Gregorc V, Santoro A, Bennicelli E, et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009;101(2):219-24
43. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012;14(6):405-15
44. Osada T, Morse MA, Hobeika A, Lyerly HK. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin Oncol 2012;39(3):305-10
45. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 2013;5(3):215-29
46. Calabrò L, Danielli R, Sigalotti L, et al. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010;37(5):460-7
47. Zhang RT, Bines SD, Ruby C, et al. TroVax(-) vaccine therapy for renal cell carcinoma. Immunotherapy 2012;4(1):27-42
48. Kim DW, Krishnamurthy V, Bines SD, et al. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin 2010;6(10):784-9
49. Al-Taei S, Salimu J, Lester JF, et al. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer 2012;77(2):312-18
50. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001;73(2):177-87
51. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011;11(2):111-21
52. Brett A, Pandey S, Fraizer G. The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer 2013;12:3
53. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010;59(10):1467-79
54. Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a "replication- restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997;57(3):466-71
55. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004;11(22):1648-58
56. Okamoto S, Kawamura K, Li Q, et al. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners. J Thorac Oncol 2012;7(5):873-82
57. Kumar P, Kratzke RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 2005;49(Suppl 1):S53-60
58. Pinton G, Brunelli E, Murer B, et al. Estrogen receptor b impacts on prognosis of human malignant mesothelioma. Cancer Res 2009;69(11):4598-604